{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:54:33Z","timestamp":1787828073071,"version":"build-2784847793"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The soluble guanylate cyclase (sGC) stimulator riociguat is approved for the treatment of pulmonary arterial hypertension and may have antifibrotic effects. However, in fibrotic tissues, oxidative stress and hypoxia can render sGC insensitive to sGC stimulators. sGC activators overcome this limitation. Here, we characterize the novel sGC activator, avenciguat, in preclinical models of SSc.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Human microvascular endothelial cells-dermal (HMVEC-d) cultured in hypoxic conditions and activated human platelet-rich plasma were incubated with varying doses of avenciguat, and the levels of TGF-\u03b22 and human CXC chemokine family ligand 4 (CXCL4) were measured, respectively. Treatment with avenciguat was analysed in mice with bleomycin-induced dermal and pulmonary fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Avenciguat reduced hypoxia-induced synthesis of TGF-\u03b22 by HMVEC-d and inhibited CXCL4 release by platelets. Moreover, avenciguat demonstrated antifibrotic effects on bleomycin-induced dermal and pulmonary fibrosis. RNA sequencing of affected skin uncovered a unique profile distinguishing avenciguat from riociguat. Avenciguat treatment resulted in deeper regulation of IFN-1 signalling and genes associated with immune response vs riociguat treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In preclinical studies, avenciguat shows the potential to influence vascular, fibrotic and immune-related processes in murine models of SSc. These studies suggest that it may offer therapeutic benefit across multiple aspects of SSc pathophysiology and support the rationale for further investigation in a Phase II clinical trial (VITALISScE\u2122; NCT05559580) of avenciguat in SSc.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf109","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T15:25:06Z","timestamp":1740065106000},"page":"4738-4743","source":"Crossref","is-referenced-by-count":6,"title":["Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5124-8864","authenticated-orcid":false,"given":"Julia","family":"Kaufman","sequence":"first","affiliation":[{"name":"Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield, CT,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8679-7078","authenticated-orcid":false,"given":"Gerald","family":"Nabozny","sequence":"additional","affiliation":[{"name":"Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield, CT,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6630-9201","authenticated-orcid":false,"given":"Cuong","family":"Tran-Manh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]},{"name":"Hiller Research Center, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4656-6646","authenticated-orcid":false,"given":"Christoph","family":"Liebel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]},{"name":"Hiller Research Center, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1082-2027","authenticated-orcid":false,"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]},{"name":"Hiller Research Center, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]},{"name":"State Key Laboratory of Genetic Engineering, School of Life Sciences and Human Phenome Institute , Fudan University , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0667-6887","authenticated-orcid":false,"given":"Lee-Anne","family":"Daley","sequence":"additional","affiliation":[{"name":"Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield, CT,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4085-5371","authenticated-orcid":false,"given":"Chao-Ting","family":"Wang","sequence":"additional","affiliation":[{"name":"Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield, CT,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7915-1159","authenticated-orcid":false,"given":"David L","family":"Ebenezer","sequence":"additional","affiliation":[{"name":"Immunology and Respiratory Diseases Research, Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield, CT,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-8374","authenticated-orcid":false,"given":"Denis","family":"Delic","sequence":"additional","affiliation":[{"name":"Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1450-9284","authenticated-orcid":false,"given":"Christian T","family":"Wohnhaas","sequence":"additional","affiliation":[{"name":"Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3345-3694","authenticated-orcid":false,"given":"Thuong","family":"Trinh-Minh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]},{"name":"Hiller Research Center, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7408-9333","authenticated-orcid":false,"given":"J\u00f6rg H W","family":"Distler","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]},{"name":"Hiller Research Center, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf , D\u00fcsseldorf,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"2025080115373979300_keaf109-B1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"2025080115373979300_keaf109-B2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025080115373979300_keaf109-B3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.20101629","article-title":"Platelet-derived serotonin links vascular disease and tissue fibrosis","volume":"208","author":"Dees","year":"2011","journal-title":"J Exp Med"},{"key":"2025080115373979300_keaf109-B4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"2025080115373979300_keaf109-B5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"2025080115373979300_keaf109-B6","doi-asserted-by":"crossref","first-page":"110189","DOI":"10.1016\/j.celrep.2021.110189","article-title":"CXCL4 drives fibrosis by promoting several key cellular and molecular processes","volume":"38","author":"Affandi","year":"2022","journal-title":"Cell Rep"},{"key":"2025080115373979300_keaf109-B7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","article-title":"Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies","volume":"74","author":"Dees","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025080115373979300_keaf109-B8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.122.001423","article-title":"The novel, clinical-stage soluble guanylate cyclase activator BI 685509 protects from disease progression in models of renal injury and disease","volume":"384","author":"Reinhart","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"2025080115373979300_keaf109-B9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2025080115373979300_keaf109-B10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025080115373979300_keaf109-B11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-021-02536-5","article-title":"An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years","volume":"23","author":"Campochiaro","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025080115373979300_keaf109-B12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/art.42781","article-title":"Effect of anti-S100A4 monoclonal antibody treatment on experimental skin fibrosis and systemic sclerosis-specific transcriptional signatures in human skin","volume":"76","author":"Trinh-Minh","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025080115373979300_keaf109-B13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/art.42033","article-title":"Impaired mitochondrial transcription factor A expression promotes mitochondrial damage to drive fibroblast activation and fibrosis in systemic sclerosis","volume":"74","author":"Zhou","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025080115373979300_keaf109-B14","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3389\/fimmu.2020.02149","article-title":"CXCL4 links inflammation and fibrosis by reprogramming monocyte-derived dendritic cells in vitro","volume":"11","author":"Silva-Cardoso","year":"2020","journal-title":"Front Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf109\/62052391\/keaf109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4738\/62052391\/keaf109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4738\/62052391\/keaf109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T19:37:45Z","timestamp":1754077065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/8\/4738\/8030225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,2,22]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf109","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,2,22]]}}}